Kyverna Therapeutics (KYTX) Accounts Payables (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Accounts Payables data on file, last reported at $11.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 36.96% year-over-year to $11.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (up 36.96% YoY), and the FY2025 full-year result was $5.3 million, up 14.75% from the prior year.
• Accounts Payables for Q1 2026 stood at $11.6 million, up from $5.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.6 million in Q1 2026 and bottomed at $3.0 million in Q3 2025.
• The 4-year median for Accounts Payables is $6.4 million (2024), against an average of $7.0 million.
• Peak annual rise in Accounts Payables reached 104.01% in 2025, while the deepest fall reached 69.63% in 2025.
• A 4-year view of Accounts Payables shows it stood at $4.4 million in 2023, then climbed by 6.1% to $4.6 million in 2024, then climbed by 14.75% to $5.3 million in 2025, then jumped by 118.68% to $11.6 million in 2026.
• The last three Accounts Payables figures came in at $11.6 million (Q1 2026), $5.3 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.

Peer Comparison